Note that MNTA has not applied for patents on Humira, Erbitux, or other FoB’s they might be thinking of working on, as far as I know. (MNTA has received a patent relating to Orencia, but it is not a process-oriented patent that would present a blueprint for a competing FoB company.)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”